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Interleukin-23 (IL-23) is an inflammatory cytokine that
plays a key role in the pathogenesis of several auto-
immune and inflammatory diseases. It orchestrates
innate and T cell-mediated inflammatory pathways
and can promote T helper 17 (Th17) cell responses.
Utilizing a T cell transfer model, we showed that IL-
23-dependent colitis did not require IL-17 secretion
by T cells. Furthermore, IL-23-independent intestinal
inflammation could develop if immunosuppressive
pathways were reduced. The frequency of naive T
cell-derived Foxp3+ cells in the colon increased in
the absence of IL-23, indicating a role for IL-23 in
controlling regulatory T cell induction. Foxp3-defi-
cient T cells induced colitis when transferred into re-
cipients lacking IL-23p19, showing that IL-23was not
essential for intestinal inflammation in the absence
of Foxp3. Taken together, our data indicate that over-
riding immunosuppressive pathways is an important
function of IL-23 in the intestine and could influence
not only Th17 cell activity but also other types of
immune responses.
INTRODUCTION
Identifying tissue-specific factors that control the immune re-
sponse is important for designing targeted therapies. Indeed,
there is increasing recognition that regional immune responses
can involve distinct effector pathways and mechanisms of con-
trol that may be different from the systemic immune response.
Recent studies have highlighted the role of IL-23 as an important
mediator of tissue inflammatory responses.
Interleukin-23 (IL-23) is a member of the IL-12 family of heter-
odimeric cytokines. It is composed of IL-12p40, which is com-
mon to IL-12, and the IL-23-specific p19 subunit (Kastelein
et al., 2007; Oppmann et al., 2000). IL-23 has been shown to
be important in a number of inflammatory diseases including ex-
perimental autoimmune encephalitis (EAE), collagen-induced
arthritis (CIA), colitis, and dermal inflammation (Cua et al., 2003;
Murphy et al., 2003; Uhlig et al., 2006b; Zheng et al., 2007). Invarious models of intestinal inflammation, IL-23 has been shown
to be preferentially expressed in the intestine rather than in the
spleen, suggesting a tissue-specific function (Hue et al., 2006;
Uhlig et al., 2006b).
In humans, increased amounts of IL-23 have been associated
with rheumatoid arthritis, multiple sclerosis, and psoriasis (Kim
et al., 2007; Lee et al., 2004; Vaknin-Dembinsky et al., 2006).
However, the relevance of IL-23 in human disease is highlighted
by the finding that polymorphisms within the IL23R gene locus
are linked to susceptibility to the two forms of inflammatory
bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis
(UC) (Duerr et al., 2006). Interestingly, that study also identified
an uncommon allele of the IL23R that confers protection against
CD. This large-scale study was further confirmed by an indepen-
dent genome-wide analysis (Wellcome Trust Case Control Con-
sortium, 2007). In addition to IL23R, this latter study also identi-
fied a linkage of CD to a region containing STAT3, a mediator of
IL-23 signaling. Together, these data strongly suggest a role for
IL-23 in human IBD. This finding correlates with results in mouse
models showing that IL-23 plays a key role in driving intestinal
inflammation mediated by innate immune cells and T cells (Elson
et al., 2007; Hue et al., 2006; Kullberg et al., 2006; Uhlig et al.,
2006b; Yen et al., 2006).
The effects of IL-23 on CD4+ T cells have mainly been linked
to the T helper 17 (Th17) cell response. Th17 cells are a recently
described T cell subset driven by the transcription factor RORgt
(Ivanov et al., 2006). They appear to mediate host protective
immunity to some extracellular bacteria and fungi and can mount
potent inflammatory responses in several mouse models of auto-
immunity, such as EAE and CIA (Weaver et al., 2007). Because IL-
23-deficient mice are resistant to both diseases, it was initially
thought that IL-23 was necessary for Th17 differentiation (Har-
rington et al., 2005; Langrish et al., 2005; Park et al., 2005). How-
ever, subsequent studies indicated that Th17 differentiation was
dependent on TGF-b and IL-6 or IL-21, whereas IL-23 could act
by reinforcing the Th17 response (Bettelli et al., 2006; Korn
et al., 2007; Mangan et al., 2006; Nurieva et al., 2007; Veldhoen
et al., 2006; Zhou et al., 2007). Thus, although IL-23 appears to
sustain Th17 responses in vivo, it is not required for Th17 polari-
zation in vitro. Elucidation of the role of IL-23 in the generation
and/or expansion of Th17 has further been hampered by the
fact that naive T cells from spleen and blood do not seem to
express the IL-23R, which appears to be induced after T cellImmunity 28, 559–570, April 2008 ª2008 Elsevier Inc. 559
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IL-23 Inhibits Foxp3 to Induce ColitisFigure 1. T Cell-Derived IL-17 Is Not Essential for Colitis
(A) Transfer of Il17a/ CD4+CD45RBhi T cells into Rag1/ mice. Left: colitis scores for recipients transferred with wild-type or IL-17-deficient CD4+CD45RBhi T
cells. Each point represents an individual mouse. Data are representative of four independent experiments; graph shows pooled data from two independent ex-
periments. Center and right: Percentage of IL-17+ (center) or IFNg+ (right) cells among CD4+ cells isolated from the colonic lamina propria from the mice analyzed
left.
(B) Characterization of Th17 and Th1 cell responses in the absence of IL-23. Amounts of IFN-g (left) and IL-17 (center) in colon homogenates ofRag1/ or Il23a/
Rag1/ mice transferred with wild-type naive T cells. Right: Amounts of RORgt mRNA in colon homogenate. Values are normalized to CD3g expression. Data
show mean + SEM of between five and ten mice from two independent experiments. *, p < 0.05; ***, p < 0.001.activation in the presence of IL-6 or IL-21 (Ivanov et al., 2006;
Zhou et al., 2007).
Although the focus of many studies has been on the IL-23-
Th17 axis, there is evidence pointing to a role for IL-23 on T cells
that is independent of IL-17 production. Thus IL-23p19-deficient
mice are resistant to EAE, whereas IL-17-deficient mice are sus-
ceptible to the disease, albeit with a delayed onset and reduced
severity (Cua et al., 2003; Komiyama et al., 2006). Furthermore,
deficiencies in IL-23 lead to susceptibility to infection with the
intestinal pathogen C. rodentium despite unimpaired induction
of a Th17 response (Mangan et al., 2006). Similarly, anti-IL-17
treatment had little impact on the T cell-mediated colitis that de-
velops in IL-10-deficient mice or in RAG-deficient recipients of
IL-10-deficient CD4+ T cells, although the colitis was dependant
on IL-23 (Yen et al., 2006).
Despite the importance of IL-23 in IBD, there remains a lack of
conclusive data on how it functions to promote T cell-dependent
colitis. Here, we have assessed T cell-mediated inflammation
in a mouse model of colitis in the presence or absence of IL-
23. Unexpectedly, our results demonstrate that IL-23 reduces
the frequency of Foxp3+ cells in the intestine and that in the ab-
sence of regulatory T (Treg) cells, IL-23 is dispensable for intes-
tinal inflammation.560 Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc.RESULTS
T Cell-Derived IL-17 Is Not Required
for Intestinal Inflammation
To dissect the role of IL-23 in colonic inflammation, we used
a well-characterized mouse model of colitis. In this model, naive
CD4+ CD45RBhi T cells transferred into immunodeficient hosts
react to the intestinal flora to induce IL-23-dependent colonic
inflammation (Hue et al., 2006; Powrie et al., 1993). Because
IL-23 promotes IL-17 production by CD4+ T cells, we reasoned
that colitis might be dependent on T cell-derived IL-17. However,
IL-17-deficient T cells are not impaired in their ability to induce
colitis (Noguchi et al., 2007) (Figure 1A). The percentage of
IFN-g-producing T cells in the intestine remains unaffected
(Figure 1A), indicating that the inflammation induced by Il17a/
T cells is not due to a compensatory increase in Th1 cells.
We next assessed the effect of IL-23 on intestinal IL-17 upon T
cell transfer. Unlike IFN-g, which was decreased in the colons of
IL-23-deficient recipients, the amount of IL-17 was unaffected by
the absence of IL-23 (Figure 1B), despite the fact that Il23a/
Rag1/ recipients did not develop intestinal inflammation
(data not shown). Likewise, lack of IL-23 did not significantly af-
fect the relative amounts of the Th17-specific factor RORgt
Immunity
IL-23 Inhibits Foxp3 to Induce Colitisin the colon (Figure 1B). Together, these data suggest that Th17
cell responses are not specifically impaired in the intestine of
IL-23-deficient mice and point to effects of IL-23 beyond Th17
promotion.
Figure 2. Reduction of Regulatory Path-
ways Increases Colitis in Il23a/Rag1/
Mice Transferred with Naive T Cells
(A) Blockade of the IL-10 pathway after transfer of
CD4+CD45RBhi T cells into Il23a/Rag1/ mice.
Left: Colitis scores for control untreated and anti-
IL-10R-treated recipients. Each point represents
an individual mouse. Right: Concentration of
proinflammatory cytokines (mean + SEM) in colon
homogenates from these mice.
(B) Blockade of TGF-b after transfer of
CD4+CD45RBhi T cells into Il23a/Rag1/
mice. Left: Colitis scores for control untreated
and anti-TGF-b treated recipients. Each point rep-
resents an individual mouse. Right: Representa-
tive microphotographs of colonic sections from
either control untreated recipients (score 3) or
recipients treated with blocking TGF-b antibody
(score 6). The scale bars represent 200 mm. Data
are pooled from two independent experiments.
*, p < 0.05; **, p < 0.01.
pathway, the one mediated by TGF-b.
TGF-b can also promote inflammation
by inducing Th17 cells. However, mice
deficient in TGF-b1 die of inflammatory
disease (Shull et al., 1992), showing that
its anti-inflammatory role is crucial for
immune homeostasis. As before, we
transferred naive CD4+ cells into Il23a/
Rag1/ mice and treated the recipients
with a blocking TGF-b antibody. As ob-
served for the IL-10 pathway, blocking
the TGF-b pathway resulted in a signifi-
cant increase in the amounts of intestinal
inflammation (Figure 2B). Although nei-
ther treatment restored the colitis levels
observed in IL-23-sufficient RAG-defi-
cient recipients upon T cell transfer (typi-
cal colitis score of 8–9), these results suggest that in the absence
of IL-23 there is a shift toward IL-10- and TGF-b-mediated im-
mune suppression that masks potential inflammatory pathways.IL-23-Independent Intestinal Inflammation
in the Absence of IL-10 or TGF-b
Inflammation is the outcome of a dynamic equilibrium between
activating and inhibitory signals. We reasoned that the ablation
of IL-23 may shift the equilibrium toward immune suppression,
which could abrogate the existing proinflammatory signals.
IL-10 has been shown to play an important role in intestinal ho-
meostasis; therefore, we used a blocking IL-10R monoclonal an-
tibody to reveal the presence of pathogenic pathways in Il23a/
Rag1/ mice. Upon naive T cell transfer, anti-IL-10R treatment
resulted in significantly increased colonic inflammation com-
pared to untreated controls (Figure 2A). Accordingly, the
amounts of the proinflammatory cytokines MCP-1 and IFN-g
were increased in colon homogenates isolated from Il23a/
Rag1/ mice that had received anti-IL-10R (Figure 2A). To val-
idate this point, we decided to block another intestinal regulatoryT Cells that Cannot Respond to TGF-b Induce Colitis
in the Absence of IL-23
We sought to further analyze the regulatory mechanisms that
become dominant in the absence of IL-23. TGF-b has been
reported to have an immunomodulatory effect on several cell
types, including T cells (Li et al., 2006). In order to study the spe-
cific effect of TGF-b on T lymphocytes, we used naive T cells iso-
lated from transgenic mice expressing a dominant-negative form
of TGF-b receptor II (called dnTGFbRII here) (Gorelik and Flavell,
2000). T cells from these mice have impaired responses to TGF-
b signals. In accordance with mAb-blockade of TGF-b, trans-
ferred dnTGFbRII T cells induced significant colitis in Il23a/
Rag1/ recipients (Figure 3A). This is all the more striking given
that dnTGFbRII-naive T cells are less colitogenic than wild-type
T cells when transferred into IL-23-sufficient mice (Fahlen
et al., 2005) and suggests that TGF-b has predominantly an
anti-inflammatory effect on CD4+ T cells in the absence of IL-23.Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc. 561
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IL-23 Inhibits Foxp3 to Induce ColitisFigure 3. Absence of TGF-b Signaling in T Cells Increases Intestinal Inflammation in Il23a/Rag1/ Mice
(A) Colitis score of Il23a/Rag1/ mice transferred with wild-type (WT) or dnTGFbRII (DN) naive T cells. Each point represents an individual mouse. Below:
Representative microphotographs of colonic sections from Il23a/Rag1/mice transferred with WT (score 2) or DN CD4+CD45RBhi T cells (score 5). The scale
bars represent 200 mm.
(B) IL-17 and IFN-g production in Il23a/Rag1/ mice transferred with wild-type (WT) or dnTGFbRII (DN) naive T cells. The figure shows representative FACS
plots of IL-17 and IFN-g production by MLN lymphocytes gated on CD4+ cells and the concentrations of IL-17 and IFN-g (mean + SEM) in the colon of transferred
Il23a/Rag1/ mice.
(C) Foxp3 expression in CD4+ cells after transfer. Left: Representative FACS plots showing Foxp3 frequency in MLN from transferred Il23a/Rag1/ mice.
Plots are gated on CD4+ TCRb+ cells. Right: Percentage of Foxp3+ among MLN CD4+ T cells of transferred Il23a/Rag1/. Each point represents an individual
mouse. Data are pooled from three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001.We then ascertained the amounts of IL-17 production by these
T cells, a process known to be highly dependent on TGF-b (Bettelli
et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006). As ex-
pected, we found that it was completely abrogated in cells with562 Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc.impaired responsiveness to TGF-b (Figure 3B). Accordingly, co-
lons from mice transferred with dnTGFbRII T cells showed very
low amounts of total IL-17 despite ongoing inflammation, indicat-
ing a minor contribution of non-T cell IL-17 in this system. In
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Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc. 563contrast, the amounts of IFN-g were significantly increased in the
colons of Il23a/Rag1/mice transferred withdnTGFbRIIT cells
(Figure 3B). These results suggest that high amounts of IFN-g
might drive the chronic intestinal inflammation in this setting.
Apart from inducing Th17 cells, TGF-b also plays a role in the
generation and survival of CD4+ Foxp3+ regulatory T cells
(Chen et al., 2003; Li et al., 2006). When we analyzed the effects
of the absence of TGF-b signaling on Foxp3 frequency after naive
T cell transfer, we found as expected that this population was al-
most completely absent among the progeny of dnTGFbRII T cells
in the spleen, mesenteric lymph node (MLN), and lamina propria
lymphocytes (LPL) (Figure 3C, and data not shown). Interestingly,
cells isolated from Il23a/Rag1/ recipients transferred with
wild-type naive CD4+ T cells contained a sizeable proportion
of Foxp3+ cells (Figure 3C), considering that the frequency of
Foxp3+ cells among naive T cells is normally very low. Although
the changes in frequency could be due to an increased influx of
Foxp3 effector cells in diseased mice, the ratio of regulatory
versus pathogenic T cells is key for the inhibition of inflammation.
We therefore hypothesized that the FoxP3+ population might be
related to the resistance to colitis observed in Il23a/Rag1/
mice. We hence assessed whether IL-23 could affect the fre-
quency of Foxp3+ cells among the progeny of naive T cells.
Absence of IL-23 Increases the Frequency
of Induced Foxp3+CD4+T Cells in the Gut
To investigate the effects of IL-23 on the frequency of Foxp3+
cells, we compared the percentage of Foxp3+ cells after naive
T cell transfer into IL-23-sufficient Rag1/ or Il23a/Rag1/
recipients. Strikingly, the absence of IL-23 increased the fre-
quency of Foxp3+ CD4+ T cells in MLN and LPL, whereas no
significant increase was observed in the spleen (Figure 4A).
Although the frequency of Foxp3+ was highest in the MLN from
both IL-23-sufficient and -deficient mice, the effect of IL-23
was most pronounced among the lymphocytes isolated from
the lamina propria. This correlates with the distribution of IL-23
expression, which is higher in the gut compared to the spleen
(Uhlig et al., 2006b).
These data suggest that naive CD4+ T cells transferred into an
empty host can become Foxp3+, but we could not exclude the
possibility that a very small number of contaminating Foxp3+
T cells proliferate to become a noteworthy population in the
absence of IL-23. Although the purity of our naive CD4+ CD25
CD45RBhi T cell population was over 99%, technical limitations
make it impossible to exclude a contamination of Foxp3+ cells
of around 0.4%. Moreover, we could also detect a very small
population of CD45RBhi Foxp3+ cells (Figure 4B), making up
around 0.2% of our starting naive population. Given that CD4+
Treg cells have been shown to expand when cotransferred
with naive T cells into immunodeficient hosts (Izcue et al.,
2006), the observed differences could indeed be due to differen-
tial accumulation of pre-existing Foxp3+ cells in the starting pop-
ulation. To gain a better insight into the origin of the Foxp3+ cells
that accumulate in the lamina propria of Il23a/Rag1/ recipi-
ents, and because we could not eliminate the contaminating
Foxp3+ population completely, we decided to include a tracer
population of preformed Foxp3+ cells (Zelenay et al., 2005).
To do so, we added 1% of sorted congenic CD45.2+ CD4+
CD45RBlow CD25+ cells (Figure 4B) to our CD45.1+ naive popu-lation. Thus, we had a CD45.2+ Foxp3+ control population arising
from pre-existing CD25+ regulatory cells and a CD45.1+ Foxp3+
population derived from the naive population, which could
also include pre-existing Foxp3+ cells. When we analyzed the
CD25+-derived Foxp3+ cells in transferred immunodeficient
mice, we found no significant differences in the tissue distribu-
tion in the presence or absence of IL-23 (Figure 4C). In contrast,
Foxp3+ cells derived from the naive T cell pool were specifically
increased in Il23a/Rag1/ recipients, especially in the colonic
lamina propria (Figure 4D). This suggests that contaminating
CD4+ CD25+ Foxp3+ do not contribute substantially to the differ-
ence in Foxp3+ frequencies observed between Il23a/Rag1/
and IL-23-sufficient Rag1/ recipients and is consistent with
a role for IL-23 in inhibiting the induction of Foxp3 on T cells.
Foxp3-Deficient Naive T Cells Induce Colitis
in the Absence of IL-23
These findings indicated that induction of CD4+ Foxp3+ T cells
may play a role in the control of inflammation in the absence of
IL-23. To test this hypothesis, we used T cells isolated from
Foxp3/ mice (Fontenot et al., 2003). Due to the aberrant T cell
activation and early mortality that occur in these mice, it was
not possible to use them as a source of naive T cells for transfer
experiments. Therefore, mixed bone-marrow chimeras were
generated with Foxp3/ (CD45.2+) and B6.SJL-Cd45 wild-type
congenic CD45.1+ donors. Mixed bone-marrow chimeras do
not develop the lymphoproliferative pathology that is characteris-
tic of mice deficient in Foxp3 (Fontenot et al., 2003). Moreover,
naive CD4+ T cells isolated from these chimeras also contain
a small contaminating Foxp3+ population, as happens with naive
cells isolated from wild-type donors. This provides an additional
control for the role of contaminating Foxp3+ cells in the starting
population. When Foxp3-deficient CD45.2+ naive T cells and
Foxp3-wild-type CD45.1+ naive T cells were isolated and trans-
ferred into immunodeficient recipients, Foxp3-deficient cells
were able to induce severe colitis in Il23a/Rag1/ recipients
(Figure 5A), whereas Foxp3-sufficient cells only induced colitis
in IL-23-sufficient Rag1/, but not Il23a/Rag1/, mice. The
level of the inflammation elicited by Foxp3-deficient cells was
similar in the presence or absence of IL-23. These results sug-
gest that IL-23 is not essential for T cell-mediated intestinal
inflammation, but is key to overriding Treg cell activity.
However, lack of Foxp3 could have an indirect effect on the na-
ture of the immune response. Foxp3+ regulatory T cells and Th17
cells appear to be generated through related pathways (Bettelli
et al., 2006). Because there is some evidence that Foxp3 can in-
hibit RORgt-induced IL-17 expression (Ivanov et al., 2006), we
wanted to check that the inflammation induced by Foxp3-defi-
cient T cells was not due to a skew toward the Th17 cell pheno-
type. As shown in Figure 5B, the absence of functional Foxp3
on naive T cells did not lead to an increased frequency of Th17
cells after transfer into Il23a/Rag1/ hosts. Similar frequen-
cies of IL-17+ cells were found in IL-23-sufficient Rag1/ hosts
(data not shown). Moreover, the total amounts of IL-17 were
not significantly increased in the colons of mice transferred with
wild-type or Foxp3-deficient naive T cells (Figure 5B). Together,
these data argue against an abnormal development of Th17 cells
in the absence of functional Foxp3 in this system and point to a di-
rect role of Foxp3 in inhibiting colitis in the absence of IL-23.
Immunity
IL-23 Inhibits Foxp3 to Induce Colitis564 Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc.
Immunity
IL-23 Inhibits Foxp3 to Induce ColitisInflamed Colons Exhibit a Similar Cytokine Pattern
in the Presence or Absence of IL-23
IL-6 and IL-21, two cytokines that promote Th17 cell polariza-
tion, have been described as directly blocking Foxp3 induction
on T cells, and in vivo IL-6 blockade increases the frequency
of Foxp3+ cells after naive T cell transfer (Figure S1 available
online), suggesting that IL-23 and IL-6 could be acting in similar
ways (Bettelli et al., 2006; Korn et al., 2007; Mangan et al., 2006;
Nurieva et al., 2007; Zhou et al., 2007). However, unlike IL-6 and
IL-21, IL-23 addition did not inhibit TGF-b-mediated Foxp3 in-
duction on naive T cells in vitro (Figure 6 and data not shown),
suggesting that the regulation of Foxp3 by IL-23 may be more
complex than the direct inhibition previously described for other
cytokines.
We next attempted to identify downstream effectors of IL-23-
mediated inflammation. IL-23 could be indirectly regulating
Foxp3 by controlling other cytokines. Indeed, colons from naive
T cell-transferred IL-23-deficient mice exhibited markedly re-
duced amounts of several proinflammatory molecules, including
IL-6 (Hue et al., 2006). However, it is difficult to distinguish
whether this is a primary or a secondary effect because of
the lack of inflammation. When we measured mRNA levels in
inflamed colons from Il23a/Rag1/ mice (Figure 6B, mice
transferred with dnTGFbRII- or Foxp3-deficient T cells), IL-6
and IL-21 were found to be upregulated to similar values as in
IL-23-sufficient Rag1/ hosts, suggesting that the effect of IL-
23 is independent of these cytokines. A similar pattern was
found for the two subunits of IL-27 (p28 and EBI3), another cyto-
kine inhibiting Foxp3 induction in vitro (Korn et al., 2007; Neufert
et al., 2007). Together, the results indicate that IL-23 is not essen-
tial for the upregulation of IL-6, IL-21, and IL-27, which can them-
selves inhibit Foxp3 induction.
Importantly, IL-23-deficient recipients transferred with Foxp3-
deficient naive T cells expressed similarly elevated amounts of
TNF-a, IFN-g, IL-6, IL-1b, KC, and MCP-1 proteins in the colon
as control Rag1/ recipients (Figure 6C). The increase in TNF-a
and IFN-g is especially relevant because these mediators have
previously been shown to be essential for the disease induction
in the naive T cell transfer model (Singh et al., 2001; Yamamoto
et al., 2000). Hence, if immunosuppressive pathways are re-
strained, IL-23 is not required for upregulation of the inflamma-
tory cytokines that induce colitis.
DISCUSSION
The immune response in the intestine is a delicate balance be-
tween effector and regulatory T cell responses. Recent studies
have shown that IL-23 plays a key role in this balance and is a nec-essary factor for the development of T cell-dependent and -inde-
pendent chronic intestinal inflammation (Elson et al., 2007; Hue
et al., 2006; Kullberg et al., 2006; Uhlig et al., 2006b; Yen et al.,
2006). The resistance of IL-23-deficient mice to colitis has been
attributed to a reduction in pathogenic T cell responses, particu-
larly those mediated by Th17 cells. Yet, in accordance with a pre-
vious report, we find that IL-17 production is not required by T
cells to induce colitis (Noguchi et al., 2007). In addition, the ab-
sence of IL-23 did not significantly alter the intestinal amounts
of IL-17 or the relative expression of RORgt in this model, sug-
gesting that IL-23 can promote intestinal inflammation indepen-
dently of its role in promoting Th17 cells. We show here that col-
itogenic T cell responses are retained in the absence of IL-23 but
are masked by dominant IL-10- and TGF-b-mediated suppres-
sion. Furthermore, transfer of naive T cells to Il23a/Rag1/
mice fails to elicit colitis and is associated with an increase in
the frequency of CD4+Foxp3+ cells in the intestine. These
Foxp3+ cells appear to play a functional role in protection from
IL-23-independent inflammation because transfer of Foxp3-defi-
cient T cells to Il23a/Rag1/ hosts induces severe colitis, in-
distinguishable from disease induced after T cell transfer into
IL-23-sufficient Rag1/ recipients. These results newly identify
an important role for IL-23 in restraining local Treg cell responses
in order to permit development of tissue inflammation.
An important concept to emerge from these studies is that fac-
tors may promote inflammation not only via direct effects on in-
flammatory mediators but also indirectly by impeding regulatory
mechanisms. Precedence for this idea comes from studies on
the role of IL-6 in pathogenic Th17 cell responses in the central
nervous system. Originally thought to be required for the devel-
opment of Th17 cell responses, it was recently shown that IL-6
promotes Th17 cell responses in part by alleviating Treg cell-me-
diated control (Korn et al., 2007). Our data strongly suggest that
IL-23 could be playing a similar role in the intestine. The fact that
Foxp3-deficient T cells can induce high levels of colitis in the ab-
sence of IL-23 provides direct evidence that IL-23 is not essential
to the pathogenesis of intestinal inflammation, if regulation is
absent. Similarly, a number of key proinflammatory cytokines, in-
cluding IL-6, IFN-g, and TNF-a, can be expressed in the intestine
in the absence of IL-23. Currently, it is not known whether the
effects of IL-23 are mediated directly on T cells or act via effects
on non-T cells that produce factors that inhibit Treg induction. IL-
23 has been suggested to act directly on T cells to inhibit Foxp3
expression (Zhou et al., 2007). However, our in vitro experiments
did not show a direct effect of IL-23 on TGF-b-mediated Foxp3
induction. It must be borne in mind that the effects of IL-23
seem specific to the intestine and could therefore require a par-
ticular environment different from conventional cell-cultureFigure 4. CD45RBhi-Derived Foxp3+ Cells Are Increased in the Colon after Naive T Cell Transfer into Il23a/Rag1/ Mice
(A) Frequency of Foxp3+ cells among CD4+ T cells from spleen, MLN, and colonic LPL from IL-23-deficient or -sufficient Rag1/ recipients transferred with
CD4+ CD25 CD45RBhi naive T cells. Each point represents an individual mouse; data are pooled from two independent experiments.
(B) Design of the congenic-transfer experiment. A mixture of 99% sorted CD45.1+ CD4+ CD25CD45RBhi naive T cells and 1% CD45.2+ CD4+ CD25+ CD45RBlow
regulatory T cells was injected into Rag1/ recipients. FACS plots show representative Foxp3 staining of sorted naive (left) and regulatory (right) populations,
gated on CD4+ cells.
(C) Approximately 2 months after transfer, cells from spleen, MLN, and colonic LP were stained for Foxp3 and the congenic marker CD45.2. Left: Representative
FACS plot showing Foxp3 versus CD45.2 expression in the spleen of transferred Il23a/Rag1/. The plot is gated on CD3+ CD4+ cells. Right: Percentage of
CD45.2+ Foxp3+ cells in the CD3+ CD4+ population in the spleen, MLN, and LP of transferred IL-23-sufficient or -deficient Rag1/ recipients. Each point rep-
resents an individual mouse.
(D) Percentage of CD45.2 Foxp3+ cells in the CD3+ CD4+ population of the mice analyzed in (C). *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc. 565
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(A) Colitis in mice transferred with Foxp3-deficient naive T cells. Left: Colitis score of Rag1/ (circles) or Il23a/Rag1/ (triangles) transferred with wild-type
or Foxp3-deficient naive T cells. Each point represents an individual mouse. Right: Representative microphotographs of colonic sections from Rag1/ mice
transferred with wild-type (score 8) or Foxp3/ naive T cells (score 10) or from Il23a/Rag1/ mice transferred with wild-type (score 4) or Foxp3/ naive T
cells (score 9). The scale bars represent 200 mm. ***, p < 0.001.
(B) Left: Percentage of IL-17-secreting cells in the CD4+ population from spleen, MLN, and colon of Il23a/Rag1/mice transferred with wild-type or Foxp3/
naive T cells. Each point represents an individual mouse. Right: Amounts of IL-17 in colon homogenate from Il23a/Rag1/ mice transferred with wild-type or
Foxp3/ naive T cells. Data show the mean + SEM of nine or ten mice. Differences were not statistically significant. Data are pooled from two independent
experiments.conditions. Alternatively, IL-23 could have an indirect effect on
Treg cell generation. Several cytokines have been described to
directly inhibit Foxp3 induction, including IL-6, IL-21, and IL-27
(Bettelli et al., 2006; Korn et al., 2007; Mangan et al., 2006;
Nurieva et al., 2007; Zhou et al., 2007). Although these cytokines
could be involved in the control of Foxp3 generation by IL-23,
IL-23 is not essential for their expression, because they are up-
regulated in inflamed colons from IL-23-deficient recipients.
This suggests that IL-23 represents a distinct tissue-specific
pathway to control Treg cell induction. Experiments with cell
type-specific deletions of the IL-23R are required to dissect
the individual components of this pathway in vivo.
By controlling Foxp3-mediated regulation, IL-23 may affect
other pathways than Th17 cell responses. Because of the role
of IL-23 in promoting IL-17 production, Th17 cells have been566 Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc.considered to play an important role in IL-23-dependent pathol-
ogies. This, however, may not be true in all cases. Although our
data do not exclude the possibility that IL-23 directly sustains
Th17 cells, they offer an additional explanation for its proinflam-
matory effects. Defects in IL-23 or IL-23R could lead to an
increase or decrease in immune suppression that could affect
not only Th17 cells, but also Th1 cells, Th2 cells, and innate im-
mune responses. Indeed, a role for IL-23 in promoting non-Th17
cell responses has already been suggested by others. Thus,
MOG-specific T cells from Il23a/ mice have reduced amounts
of IFN-g, and systemic IL-23 can enhance Th1 cell antitumor re-
sponses (Kaiga et al., 2007; Thakker et al., 2007). Interestingly,
both IL-23-deficient and -sufficient colitic mice showed in-
creased amounts of intestinal IFN-g, indicating a strong local
Th1 response. CD4+ T lymphocytes and non-T cells have been
Immunity
IL-23 Inhibits Foxp3 to Induce ColitisFigure 6. Cytokine Expression in Inflamed Colons from Il23a/Rag1/ Mice
(A) Foxp3 expression after culture of CD4+CD45RBhi T cells with TGF-b, IL-23, and/or IL-21. Left: Representative FACS plots. Cells are gated on forward and side
scatter to exclude dead cells. Right: Percentage of Foxp3+ cells in the CD4+ population. Data show mean + SEM of three replicates and are representative of three
independent experiments. ns, not significant.
(B) Relative mRNA expression of IL-6, IL-21, IL-27p28, and EBI3 in colon homogenates after naive T cell transfer with wild-type (empty columns) or dnTGFbRII or
Foxp3/ CD4+ T cells (filled columns). Data from mice transferred with dnTGFbRII or Foxp3/ T cells were pooled because they yielded similar values. Data
were normalized to HPRT for each sample. The average value for Il23a/Rag1/ mice transferred with wild-type T cells (noninflamed) was set as one. Data
show mean + SEM of between seven and 11 mice per group. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.
(C) Amounts of proinflammatory cytokines in colon homogenates of Rag1/ or Il23a/Rag1/ transferred with Foxp3/ naive T cells. Data show mean + SEM
of between five and ten mice from two independent experiments. None of the differences were significant.identified as sources of intestinal IFN-g in different models of
colitis (Hue et al., 2006; Uhlig et al., 2006a). Indeed, the Th1
response has been shown to be involved in the pathogenesis
of T cell transfer-mediated colitis and both IFN-g and the Th1cell-specific transcription factor T-bet play functional roles
(Neurath et al., 2002; Powrie et al., 1994). Similarly, CD in humans
has been linked to exacerbated Th1 cell responses (Cobrin and
Abreu, 2005). IL-12 is known to play a pivotal role in the control ofImmunity 28, 559–570, April 2008 ª2008 Elsevier Inc. 567
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ment of inflammation varies depending on the model. By con-
trast with chronic models, acute inflammation linked to intestinal
injury is IL-12-dependent and inhibited by IL-23 (Becker et al.,
2006). Clearly, further studies are required to fully characterize
the contributions of these two cytokines to intestinal inflamma-
tion in different models and in particular in human disease. Nev-
ertheless, by controlling Foxp3, IL-23 could be permissive for the
development of both Th1 and Th17 cell responses.
Strikingly, IL-23 reduced the percentage of naive T cell-de-
rived Foxp3+ but had little impact on the frequency of the prog-
eny from already developed Treg cells. Foxp3+ Treg cells can de-
velop in the thymus (the so-called naturally arising Treg cells), but
also be induced in the periphery. Recent data from our group and
others have shown that Foxp3+ Treg cells can be induced in the
intestine by a mechanism depending on TGF-b and retinoic acid
(Coombes et al., 2007; Mucida et al., 2007; Sun et al., 2007).
These Treg cells are induced by a specific subset of dendritic
cells (DCs) expressing CD103, which is enriched in the GALT.
In contrast to the CD103+ subset, CD103 DCs isolated from
the MLN do not induce Foxp3+ cells. Importantly, they express
high amounts of IL-23p19 mRNA compared to the Treg cell-in-
ducing CD103+ subset upon CD40 stimulation (Coombes
et al., 2007). It is tempting to speculate that IL-23, together
with TGF-b and RA, is one of several factors that decide whether
a naive T cell will become regulatory and induce dominant toler-
ance toward its cognate antigen. Other factors could include Th1
cell-related cytokines. A recent report signaled no increase of
CD4+CD25+Foxp3+ cells in Il12b/ Ifng/ mice, which lack
both IL-12 and IL-23 (Wang et al., 2007). The analysis was, how-
ever, performed on the spleen, not on intestinal cells, where we
find the highest effect of IL-23. More research is required to elu-
cidate the contribution of different cytokines to the homeostasis
of Treg cells under steady-state conditions.
It should be noted that although immune regulatory pathways
in the intestine prevent hyperreactivity toward dietary antigens
and harmless commensal flora, they can prove a double-edged
sword. It is imperative to the host to mount protective responses
toward intestinal pathogens, and hence it is necessary to tempo-
rarily overcome dominant suppression and Treg cell activity. IL-6
has been identified as one such inflammatory mediator that de-
sensitizes T cells to Treg cell-mediated suppression (Pasare and
Medzhitov, 2003). IL-23, via its ability to impede Treg cell re-
sponses in the intestine, may promote host-protective immunity
at this site. In support of this, IL-23-deficient mice, unlike wild-
type mice, do not develop severe colitis after infection with the
intestinal pathogen C. rodentium, but they fail to clear the bacte-
ria and die within 2 weeks (Mangan et al., 2006).
In the years since the identification of IL-23, evidence has ac-
cumulated indicating that IL-23 orchestrates different aspects
of the immune response in tissues. In addition to its proinflamma-
tory action on the innate immune system and its proposed role in
sustaining Th17 cell responses, we have identified the overcom-
ing of Foxp3-mediated regulation as another key function of IL-23
during immune responses. Although the relevance of this mech-
anism in other experimental models and human disease remains
to be ascertained, this could have important implications for both
the understanding of mucosal immunity and designing therapeu-
tic approaches to IL-23-dependent diseases.568 Immunity 28, 559–570, April 2008 ª2008 Elsevier Inc.EXPERIMENTAL PROCEDURES
Mice
Wild-type C57BL/6, BALB/c, CD4-restricted dnTGFbRII C57BL/6, congenic
B6.SJL-Cd45, C57BL/6 Rag1/, BALB/c Rag2/, C57BL/6 Il17a/,
C57BL/6 Il23a/ Rag1/, and C57BL/6 Foxp3/ mice were bred and main-
tained under specific pathogen-free conditions in accredited animal facilities
at the University of Oxford. Experiments were conducted in accordance with
the UK Scientific Procedures Act of 1986. Mice were negative for Helicobacter
spp. and other known intestinal pathogens and were more than 6 weeks old
when first used.
Generation of Mixed Bone-Marrow Chimeras
Bone marrow isolated from 2- to 3-week-old B6.Foxp3/ mice was depleted
of T cells via anti-CD4 and anti-CD8 Abs together with anti-rat coated Dyna-
beads (Dynal). B6.Foxp3/ bone marrow was then mixed in a 1:1 ratio with
bone marrow taken from B6.SJL-Cd45 mice and injected intravenously into
gamma-irradiated (5.5 Gy, 550 rad) B6 SJL CD45.1 mice. Eight weeks later,
Foxp3/ and wild-type naive T cells were sorted on the basis of expression
of CD4, CD25, CD45RB, and CD45.2.
Transfer of Naive CD4+CD45RBhi T Cells
Naive CD4+CD45RBhi T cells were isolated from spleens of C57BL/6 or
C57BL/6 Il17a/ mice via FACS sorting as previously described (Read
et al., 2000). In brief, after enriching for CD4+ lymphocytes, single-cell suspen-
sions were stained with PerCP-conjugated anti-CD4, PE-conjugated anti-
CD25, and FITC–anti-CD45RB (all obtained from BD Biosciences). Naive
CD4+CD25CD45RBhi T cells were purified (>99%) with a cell sorter (MoFlo;
DakoCytomation). For isolation of cells from bone-marrow chimeras, cells
were additionally stained with biotinylated anti-CD45.2 followed by streptavi-
din-APC (both from BD Biosciences). For some experiments, the CD4+ CD25+
CD45RBlow population was sorted and added in a 1:100 ratio to the naive
population. Sex-matched RAG1/ recipient mice received 4 3 105
CD4+CD45RBhi T cells by intraperitoneal (i.p.) injection, and development of
intestinal inflammation was monitored as described below.
In Vivo Antibody Treatment
Anti-mouse IL-10R mAb (clone 1B1.2) (O’Farrell et al., 1998) and anti-mouse
TGF-b1/2 (clone 1D11.16.8) (Dasch et al., 1989) were purified from hybridoma
supernatant by affinity chromatography and shown to contain less than 1.0
endotoxin units per milligram of protein. Mice were injected i.p. with 0.5 mg
of anti-IL-10R twice a week, or with 1 mg of anti-TGF-b three times a week,
starting the day after the T cell transfer and lasting until the end of the experi-
ment.
Assessment of Intestinal Inflammation
Mice were killed when symptoms of clinical disease (significant weight loss or
diarrhea) became apparent in control groups, usually around 8 weeks after ini-
tiation of experiments. Samples of proximal colon, mid-colon, and distal colon
were immediately fixed in buffered 10% formalin. Four to five microns of
paraffin-embedded sections were stained with hematoxylin and eosin, and in-
flammation was assessed with a modified version of a previously described
scoring system (Read et al., 2000). Each sample was graded semiquantita-
tively from 0 to 3 for the four following criteria: degree of epithelial hyperplasia
and goblet cell depletion; leukocyte infiltration in the lamina propria; area of tis-
sue affected; and the presence of markers of severe inflammation such as
crypt abscesses, submucosal inflammation, and ulcers. Scores for each crite-
rion were added to give an overall inflammation score for each sample of 0–12.
The total colonic score was calculated as the average of the individual scores
from the sections of proximal colon, mid-colon, and distal colon. In the graphs
shown, each point corresponds to an individual mouse. Micrographs show
sections of mid-colon.
Isolation of Leukocyte Subpopulations and FACS
Cell suspensions were prepared from spleen, MLN, and the LP as previously
described (Uhlig et al., 2006a). The following antibodies were used for flow
cytometry: anti-CD4 conjugated to PerCPorFITC, anti-mouse TCR-bconjugated
to PE, biotinylated anti-CD45.2 (all from BD Biosciences), and anti-CD3
Immunity
IL-23 Inhibits Foxp3 to Induce Colitisconjugated to Alexa 647 (eBiosciences). Biotinylated antibodies were de-
tected with PerCP-conjugated streptavidin (BD Biosciences). For Foxp3 stain-
ing, cells were fixed in eBioscience Fix/Perm buffer after the surface staining,
followed by permeabilization in eBioscience buffer and staining for Foxp3 con-
jugated to APC or FITC (eBioscience) according to the manufacturer’s instruc-
tions. Cells were acquired with a FACSCalibur or FACSort (BD Biosciences)
and analyzed with FlowJo (Tree Star). For staining of intracellular cytokines,
cells were cultured for 4 hr as described (Uhlig et al., 2006a). After this in vitro
stimulation, cells were stained for CD4 and then fixed in Fix/Perm buffer (eBio-
science). This was followed by permeabilization in eBioscience buffer and
staining with anti-IFN-g APC, anti-IL-17 PE (all from BD Biosciences), anti-
Foxp3-APC (eBioscience), or appropriate isotype controls (BD Biosciences).
In Vitro Foxp3 Induction
Sorted CD4+ CD25 CD45RBhi T cells from C57BL/6 mice were resuspended
in complete RPMI 5% FCS and incubated at 2.53 105 cells/ml in the presence
of Dynabeads Mouse CD3/CD28 T cell expander (Dynal, 2 ml/ml) and in the
presence of TGF-b (R&D, 1 ng/ml), IL-23 (eBioscience, 10 ng/ml), and/or IL-
21 (R&D, 50 ng/ml). Foxp3 expression was assessed by FACS after 72 hr.
Quantitation of Cytokine Amounts in Intestinal Tissues
Frozen colonic tissue samples were processed as described (Hue et al., 2006).
Sequences for primers sets and probes are described in the Supplemental
Data. Protein concentrations were measured either with the cytometric bead
assay (BD Biosciences) (IFN-g, IL-6, TNF-a, MCP-1) or with the Luminex 100
assay (Bio-Rad Laboratories) (IL-1b, IL-17, KC), as described (Hue et al.,
2006).
Statistics
The nonparametric Mann-Whitney test was used for comparing pathology
scores and data from colon homogenates, and an unpaired t test was used
to examine percentages of Foxp3+, IFN-g+, and IL-17+ cells. Differences
were considered statistically significant when p < 0.05.
SUPPLEMENTAL DATA
Primers and probe sequences, as well as one figure, are available at http://
www.immunity.com/cgi/content/full/28/4/559/DC1/.
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